PuSH - Publikationsserver des Helmholtz Zentrums München

Straube, C. ; Kessel, K.A. ; Zimmer, C.* ; Schmidt-Graf, F.* ; Schlegel, J.* ; Gempt, J.* ; Meyer, B.* ; Combs, S.E.

A second course of radiotherapy in patients with recurrent malignant gliomas: Clinical data on re-irradiation, prognostic factors, and usefulness of digital biomarkers.

Curr. Treat. Options Oncol. 20:71 (2019)
Verlagsversion DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The treatment of malignant gliomas has undergone a significant intensification during the past decade, and the interdisciplinary treatment team has learned that all treatment opportunities, including surgery and radiotherapy (RT), also have a central role in recurrent gliomas. Throughout the decades, re-irradiation (re-RT) has achieved a prominent place in the treatment of recurrent gliomas. A solid body of evidence supports the safety and efficacy of re-RT, especially when modern techniques are used, and justifies the early use of this regimen, especially in the case when macroscopic disease is present. Additionally, a second adjuvant re-RT to the resection cavity is currently being investigated by several investigators and seems to offer promising results. Although advanced RT technologies, such as stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT) have become available in many centers, re-RT should continue to be kept in experienced hands so that they can select the optimal regimen, the ideal treatment volume, and the appropriate techniques from their tool-boxes. Concomitant or adjuvant use of systemic treatment options should also strongly be taken into consideration, especially because temozolomide (TMZ), cyclohexyl-nitroso-urea (CCNU), and bevacizumab have shown a good safety profile; they should be considered, if available. Nonetheless, the selection of patients for re-RT remains crucial. Single factors, such as patient age or the progression-free interval (PFI), fall too short. Therefore, powerful prognostic scores have been generated and validated, and these scores should be used for patient selection and counseling.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Glioblastoma ; Re-irradiation ; Radiotherapy ; Recurrent Glioblastoma ; Treatment ; Patient Selection; High-grade Glioma; Amino-acid Pet; Glioblastoma-multiforme; Stereotactic Radiosurgery; Complete Resection; Tumor Volume; Phase-ii; Survival; Temozolomide; Multicenter
ISSN (print) / ISBN 1527-2729
e-ISSN 1534-6277
Quellenangaben Band: 20, Heft: 9, Seiten: , Artikelnummer: 71 Supplement: ,
Verlag Springer
Verlagsort 233 Spring St, New York, Ny 10013 Usa
Begutachtungsstatus Peer reviewed